The peptide synthesis market was valued at USD 961.4 million in 2024. It is projected to reach USD 1,840.6 million by 2033, growing at a CAGR of 7.8% from 2025 to 2033, according to Grand View Research. Demand for peptide-based drugs, faster synthesis technologies and wider use across pharma and biotech are pushing the market forward.

Market Size and Growth Outlook

The forecast adds roughly USD 879 million in annual revenue between 2024 and 2033. That means the industry is on track to nearly double in nine years. A 7.8% CAGR is steady rather than explosive, so the more interesting story is which segments capture the growth, not the headline number.

Regional momentum differs sharply. North America led the global peptide synthesis market in 2024, supported by a mature pharmaceutical sector, favorable regulation and a strong biopharma focus. Asia Pacific is expected to grow faster at 9.33%, about 1.5 percentage points above the global rate. Lower manufacturing costs are encouraging drug developers to outsource peptide production there.

Key Growth Drivers of the Peptide Synthesis Market

Rising Demand for Peptide Therapeutics

Peptides combine high specificity, low toxicity and strong biocompatibility. That makes them attractive for chronic conditions such as diabetes, obesity, cancer and cardiovascular disease. The report lists approvals including Mounjaro (tirzepatide, 2022) and Rybelsus (semaglutide, 2019), and the growing clinical pipeline is raising demand for high-purity and custom peptides.

Investment follows the same pattern. CordenPharma announced a large-scale expansion at its Colorado site in July 2024 to meet GLP-1 peptide demand. Granules India acquired Swiss CDMO Senn Chemicals AG in 2025 to enter peptide therapeutics.

Download a free sample report or claim your copy of this full market intelligence report

Looking for more in-depth data focusing on specific segments or regions?

Technology and Automation Breakthroughs

Advances in automation, resin chemistry, coupling reagents and purification have cut production time and improved consistency. Some recent examples from the report:

• Asymchem reported fully automated peptide drug production in November 2024.
• BioDuro opened an automated solid-phase scale-up lab in Shanghai in January 2025, supporting synthesis up to 800 mmol.
• Biotage's PeptiPEC-96 purifies up to 96 peptides at once. It is 75% faster than traditional RP-HPLC and cuts solvent use by up to 98%.

Consolidation, Regulation and Regional Expansion

Mergers and acquisitions signal a market where capacity and intellectual property are worth buying. Regulation shapes demand as well. FDA, EMA and ICH requirements for GMP compliance and high purity push developers toward certified suppliers. Meanwhile, rising healthcare spending in Asia Pacific, Latin America and the Middle East is opening new demand pools.

Major Peptide Synthesis Market Segments

By Product

Reagents and consumables held 47.97% of revenue in 2024. They include amino acids, coupling reagents, resins, solvents and protecting groups, and synthesis cannot run without them. Equipment is expected to post a significant CAGR because it scales well and can be tailored to specific needs.

By Technology

Many readers assume solid-phase synthesis leads the field, but liquid phase peptide synthesis (LPPS) held the largest share at 44.04% in 2024. LPPS is valued for scalability, purity and cost-effectiveness, especially for shorter sequences at larger volumes. Cambrex's 2024 LPPS approach uses conventional API batch reactors and continuous flow, which reduces solvent and excess reagent use. Hybrid technology is forecast to grow fastest, as combining approaches delivers high purity and yield.

By Application

Therapeutics accounted for 70.35% of revenue in 2024, driven by demand for better metabolic stability and target specificity. Diagnosis is expected to grow fastest, because peptides offer the sensitivity and specificity that diagnostic assays need.

By End Use

Pharmaceutical and biotechnology companies led with 66.74% of revenue in 2024. CDMOs and CROs are forecast to grow fastest as drug developers outsource specialized peptide work.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Competitive Landscape

Key players named in the report include Thermo Fisher Scientific, Merck KGaA, GenScript, Bachem Holding AG, Biotage, Creative Diagnostics, PolyPeptide Group, Syngene International, Puresynth Research Chemicals and Lonza. Bachem announced capacity expansions in Switzerland, California and the UK in May 2025, while Lonza restructured its CDMO business under a "One Lonza" strategy in December 2024.

Unique Insights Beyond the Headline Numbers

The following points are my interpretation of the report's data, not statements from the source.

The fastest growth sits outside the largest segments. Hybrid technology, diagnosis and CDMOs and CROs each lead on growth rate but trail the dominant segments on current share. The next phase of the peptide synthesis market may be shaped by outsourcing, hybrid workflows and diagnostics more than by traditional in-house therapeutic production.

Consumables may give the steadiest revenue. Since nearly half of revenue comes from reagents and consumables, which are used up in every run, suppliers benefit from recurring demand.

Sustainability is becoming a competitive factor. Donaldson and PolyPeptide piloted a solvent recovery system in 2024 to recycle acetonitrile. Along with Cambrex's lower-solvent LPPS and Biotage's 98% solvent reduction, this suggests that solvent efficiency is turning into a selling point in the industry.

Explore the full list of profiled companies operating in this market with recent strategic initiatives